| Literature DB >> 35207630 |
Ru-Yi Lu1, Heng-Kai Zhu2, Xiang-Yan Liu2, Li Zhuang2, Zhuo-Yi Wang2, Yuan-Li Lei3, Ting Wang2, Shu-Sen Zheng2.
Abstract
This study aimed to explore the correlation between preoperative total bilirubin (TBil) level and postoperative delirium (POD) in orthotopic liver transplantation (OLT). All the OLT consecutively performed between April 2019 and March 2021 were retrospectively reviewed with data retrieved from a prospectively collected database. Logistic regression model and generalized additive model were used to identify both linear and non-linear relationships between TBil and POD. A two-piecewise regression model was performed to calculate the saturation effect. Subgroup analyses were performed using stratified logistic regression models. A total of 402 recipients were enrolled. After fully adjusted for covariates, TBil was indicated to have a non-linear relationship with POD. The two-piecewise regression model showed the inflection point was 20 mg/dL. On the left side of the inflection point, the incidence of POD increased by 5% per 1 mg/dL increment of TBil (p = 0.026). On the right side of the inflection point, the effect size had no statistical significance (OR, 0.97; 95% CI, 0.90-1.05; p = 0.482). The relationship between preoperative TBil level and POD incidence is non-linear in OLT recipients. The incidence of POD is positively correlated with TBil level when it is below 20 mg/dL. A saturation effect is observed when TBil level reaches 20 mg/dL.Entities:
Keywords: generalized additive models; liver transplantation; postoperative delirium; saturation effect; total bilirubin
Year: 2022 PMID: 35207630 PMCID: PMC8879947 DOI: 10.3390/jpm12020141
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Figure 1Flowchart analyzing the effect of preoperative total bilirubin on postoperative delirium after liver transplantation.
Baseline characteristics of patients underwent liver transplantation.
| Preoperative Total Bilirubin Level | T1 | T2 | T3 | |
|---|---|---|---|---|
|
| 139 | 139 | 124 | |
| Pre-transplant characteristics | ||||
| Age, years, mean ± SD | 54 ± 10 | 51 ± 10 | 50 ± 10 | 0.003 |
| Male, | 122 (87.8%) | 116 (83.5%) | 101 (81.5%) | 0.349 |
| BMI, mean ± SD | 22.6 ± 2.9 | 24.0 ± 4.0 | 22.8 ± 3.7 | 0.002 |
| MELD score at transplant, median (IQR) | 10 (8–12) | 16 (14–20) | 28 (24–33) | <0.001 |
| Total bilirubin, mg/dL, mean ± SD | 1.1 ± 0.4 | 4.3 ± 2.4 | 22.1 ± 7.6 | <0.001 |
| Creatinine, mg/dL, mean ± SD | 0.9 ± 0.6 | 0.8 ± 0.3 | 1.0 ± 0.9 | 0.076 |
| INR, mean ± SD | 1.3 ± 0.3 | 1.7 ± 0.5 | 2.4 ± 1.0 | <0.001 |
| Serum sodium, mmol/L, median (IQR) | 140 (138–141) | 138 (135–141) | 136 (133–139) | <0.001 |
| Liver diseases | ||||
| Hepatitis B, | 118 (84.9%) | 103 (74.1%) | 88 (71.0%) | 0.018 |
| Malignancy, | 37 (26.6%) | 57 (41.0%) | 73 (58.9%) | <0.001 |
| Hepatitis C, | 1 (0.7%) | 1 (0.7%) | 2 (1.6%) | 0.692 |
| Encephalopathy, | 6 (4.3%) | 19 (13.7%) | 45 (36.3%) | <0.001 |
| Artificial liver support, | 1 (0.7%) | 13 (9.4%) | 57 (46.0%) | <0.001 |
| RRT, | 1 (0.7%) | 6 (4.3%) | 13 (10.5%) | 0.001 |
| Alcohol consumption, | 22 (15.8%) | 30 (21.6%) | 26 (21.0%) | 0.416 |
| Diabetes mellitus, | 26 (18.7%) | 18 (12.9%) | 17 (13.7%) | 0.352 |
| Hypertension, | 31 (22.3%) | 28 (20.1%) | 19 (15.3%) | 0.347 |
| Cardiovascular disease, | 9 (6.5%) | 7 (5.0%) | 5 (4.0%) | 0.669 |
| Donation and transplantation surgery | ||||
| DBD, | 57 (41.0%) | 65 (46.8%) | 48 (38.7%) | 0.390 |
| Graft weight, g, mean ± SD | 1447 ± 352 | 1488 ± 349 | 1486 ± 388 | 0.575 |
| ABO compatible transplantation, | 132 (95.0%) | 127 (91.4%) | 97 (78.2%) | <0.001 |
| Intraoperative transfusion | ||||
| RBC, u, median (IQR) | 2.0 (0.0–6.0) | 4.0 (2.0–8.5) | 6.0 (4.0–9.0) | <0.001 |
| FFP, mL, median (IQR) | 750 (600–970) | 800.0 (650–1085) | 845 (750–1170) | <0.001 |
| Auto-transfusion, mL, median (IQR) | 250 (0–500) | 250 (0–500) | 250 (0–500) | 0.444 |
| Intraoperative bleeding, mL, median (IQR) | 1000 (800–1500) | 1500 (1000–2000) | 1500 (1000–1850) | <0.001 |
| Intraoperative urine output, mL, median (IQR) | 1200 (800–1675) | 1050 (700–1600) | 810 (300–1350) | <0.001 |
| Intraoperative RRT, | 6 (4.3%) | 8 (5.8%) | 29 (23.4%) | <0.001 |
| Post-transplant ammonia, umol/L, median (IQR) | 50 (39–66) | 46 (34–64) | 49 (32–75) | 0.298 |
| Post-transplant sedatives, | 29 (20.9%) | 26 (18.7%) | 25 (20.2%) | 0.900 |
| Postoperative delirium, | 14 (10.1%) | 27 (19.4%) | 37 (29.8%) | <0.001 |
| Total bilirubin in day 7 after LT, mg/dL, median (IQR) | 1.1 (0.8–1.7) | 1.7 (1.3–2.7) | 3.3 (2.3–5.7) | <0.001 |
p < 0.05 was considered statistically significant. BMI, body mass index; DBD, donation after brain death; FFP, fresh frozen plasma; INR, international normalized ratio; IQR, interquartile range; LT, liver transplantation; MELD, model for end-stage liver disease; RBC, red blood cell; RRT, renal replacement therapy.
Predictors of post-transplant delirium by univariate analysis.
| Statistics | OR (95%CI) | ||
|---|---|---|---|
| Age | 52 ± 10 | 1.01 (0.98, 1.03) | 0.578 |
| Gender | |||
| Male | 339 (84.3%) | 1 | |
| Female | 63 (15.7%) | 0.86 (0.43, 1.74) | 0.671 |
| BMI | 23.1 ± 3.6 | 1.03 (0.96, 1.10) | 0.375 |
| Total bilirubin | 8.7 ± 10.1 | 1.04 (1.02, 1.07) | <0.001 |
| Creatinine | 0.9 ± 0.6 | 1.36 (0.98, 1.90) | 0.070 |
| INR | 1.8 ± 0.8 | 1.60 (1.23, 2.14) | <0.001 |
| Sodium | 138 (135–141) | 0.98 (0.96, 1.00) | 0.095 |
| Hepatitis B | |||
| No | 93 (23.1%) | 1 | |
| Yes | 309 (76.9%) | 0.84 (0.48, 1.49) | 0.559 |
| Malignancy | |||
| No | 235 (58.5%) | 1 | |
| Yes | 167 (41.5%) | 1.86 (1.13, 3.06) | 0.015 |
| Encephalopathy | |||
| No | 332 (82.6%) | 1 | |
| Yes | 70 (17.4%) | 2.92 (1.65, 5.17) | <0.001 |
| Artificial liver support | |||
| No | 331 (82.3%) | 1 | |
| Yes | 71 (17.7%) | 2.62 (1.48, 4.64) | 0.001 |
| RRT | |||
| No | 382 (95.0%) | 1 | |
| Yes | 20 (5.0%) | 1.85 (0.69, 4.97) | 0.225 |
| Alcohol consumption | |||
| No | 324 (80.6%) | 1 | |
| Yes | 78 (19.4%) | 1.32 (0.73, 2.40) | 0.362 |
| Diabetes mellitus | |||
| No | 341 (84.8%) | 1 | |
| Yes | 61 (15.2%) | 1.02 (0.51, 2.03) | 0.954 |
| Hypertension | |||
| No | 324 (80.6%) | 1 | |
| Yes | 78 (19.40%) | 0.89 (0.47, 1.68) | 0.718 |
| Cardiovascular disease | |||
| No | 381 (94.8%) | 1 | |
| Yes | 21 (5.2%) | 1.32 (0.47, 3.72) | 0.601 |
| Donation type | |||
| DBD | 170 (42.3%) | 1 | |
| DCD | 232 (57.72%) | 1.30 (0.78, 2.17) | 0.310 |
| Graft weight | 1473 ± 362 | 1.00 (1.00, 1.00) | 0.289 |
| ABO compatibility | |||
| ABO-i | 46 (11.4%) | 1 | |
| ABO-c | 356 (88.6%) | 0.74 (0.36, 1.53) | 0.413 |
| RBC | 4.0 (2.0–8.0) | 1.02 (0.97, 1.07) | 0.388 |
| FFP | 800 (630–1020) | 1.00 (1.00, 1.00) | 0.982 |
| Auto-transfusion | 250 (0–500) | 1.00 (1.00, 1.00) | 0.017 |
| Intraoperative bleeding | 1200 (800–2000) | 1.00 (1.00, 1.00) | 0.423 |
| Intraoperative urine output | 1050 (650–1600) | 1.00 (1.00, 1.00) | 0.053 |
| Intraoperative RRT | |||
| No | 359 (89.3%) | 1 | |
| Yes | 43 (10.7%) | 1.96 (0.97, 3.96) | 0.061 |
| Post-transplant ammonia | 49 (35–67) | 1.01 (1.00, 1.01) | 0.033 |
| Post-transplant sedatives | |||
| No | 322 (80.1%) | 1 | |
| Yes | 80 (19.9%) | 1.39 (0.77, 2.50) | 0.273 |
p < 0.05 was considered statistically significant. ABO-c, ABO compatible; ABO-i, ABO incompatible; BMI, body mass index; DBD, donation after brain death; DCD, donation after cardiac death; FFP, fresh frozen plasma; INR, international normalized ratio; RBC, red blood cell; RRT, renal replacement therapy.
Relationship between total bilirubin and post-transplant delirium in different models.
| Variable | Crude Model | Minimally Adjusted Model | Fully Adjusted Model | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||
| Total bilirubin (per 1 mg/dL) | 1.04 (1.02, 1.07) | <0.001 | 1.05 (1.02, 1.07) | <0.001 | 1.03 (0.99, 1.06) | 0.104 |
| Total bilirubin (tertiles) | ||||||
| T1 | Reference | Reference | Reference | |||
| T2 | 2.15 (1.08, 4.31) | 0.030 | 2.29 (1.14, 4.62) | 0.020 | 2.02 (0.97, 4.22) | 0.060 |
| T3 | 3.80 (1.94, 7.44) | <0.001 | 4.20 (2.11, 8.38) | <0.001 | 2.46 (1.06, 5.69) | 0.035 |
| <0.001 | <0.001 | 0.035 | ||||
Crude model: did not adjust covariates. Minimally adjusted model: adjusted for age and gender. Fully adjusted model: adjusted for age, gender, creatinine, international normalized ratio, sodium, malignancy, encephalopathy, artificial liver support, auto-transfusion, intraoperative renal replacement therapy, and post-transplant ammonia.
Figure 2The non-linear relationship between preoperative total bilirubin and POD. A non-linear relationship between them was identified after adjusting for age, gender, creatinine, international normalized ratio, sodium, malignancy, encephalopathy, artificial liver support, auto-transfusion, intraoperative renal replacement therapy, and post-transplant ammonia. POD, postoperative delirium.
The results of two-piecewise regression model.
| The Inflection Point of Total Bilirubin (Per 1 mg/dL) | OR | 95% CI | |
|---|---|---|---|
| ≤20 | 1.05 | 1.01 to 1.11 | 0.026 |
| >20 | 0.97 | 0.90 to 1.05 | 0.482 |
Effect: postoperative delirium. Cause: preoperative total bilirubin. Adjusted for age, gender, creatinine, international normalized ratio, sodium, malignancy, encephalopathy, artificial liver support, auto-transfusion, intraoperative renal replacement therapy, and post-transplant ammonia.
Effect size of preoperative total bilirubin on postoperative delirium in prespecified and exploratory subgroups.
| Characteristics | No. of Patients | OR (95% CI) | |
|---|---|---|---|
| Age, years | |||
| ≤55 | 255 | 1.03 (1.00, 1.07) | 0.452 |
| >55 | 147 | 1.01 (0.95, 1.08) | |
| Gender | |||
| Male | 339 | 1.03 (1.00, 1.07) | 0.976 |
| Female | 63 | 1.02 (0.91, 1.16) | |
| BMI | |||
| ≤22 | 164 | 1.07 (1.01, 1.14) | 0.006 |
| >22 | 238 | 1.00 (0.96, 1.04) | |
| MELD | |||
| ≤22 | 271 | 1.06 (0.98, 1.15) | 0.485 |
| >22 | 131 | 1.00 (0.96, 1.05) | |
| Hepatitis B | |||
| No | 93 | 1.08 (1.00, 1.16) | 0.388 |
| Yes | 309 | 1.02 (0.98, 1.06) | |
| Malignancy | |||
| No | 235 | 1.04 (0.99, 1.09) | 0.201 |
| Yes | 167 | 1.00 (0.95, 1.05) | |
| Encephalopathy | |||
| No | 332 | 1.02 (0.99, 1.06) | 0.115 |
| Yes | 70 | 1.00 (0.94, 1.07) | |
| Artificial liver support | |||
| No | 331 | 1.03 (1.00, 1.07) | 0.036 |
| Yes | 71 | 0.99 (0.93, 1.05) | |
| Alcoholic consumption | |||
| No | 324 | 1.02 (0.99, 1.06) | 0.870 |
| Yes | 78 | 1.06 (0.99, 1.15) | |
| Diabetes mellitus | |||
| No | 341 | 1.02 (0.99, 1.06) | 0.959 |
| Yes | 61 | 1.12 (0.99, 1.27) | |
| Hypertension | |||
| No | 324 | 1.01 (0.98, 1.05) | 0.375 |
| Yes | 78 | 1.10 (1.01, 1.19) | |
| RBC transfusion, u | |||
| ≤5 | 226 | 0.99 (0.94, 1.05) | 0.234 |
| >5 | 176 | 1.04 (0.99, 1.08) | |
| Auto-transfusion | |||
| No | 167 | 1.01 (0.96, 1.08) | 0.358 |
| Yes | 235 | 1.03 (0.99, 1.07) | |
| Intraoperative bleeding, mL | |||
| ≤1000 | 183 | 1.01 (0.95, 1.07) | 0.194 |
| >1000 | 219 | 1.03 (0.99, 1.07) | |
| Intraoperative urine output | |||
| ≤1000 | 196 | 1.04 (1.00, 1.09) | 0.892 |
| >1000 | 206 | 1.01 (0.96, 1.07) | |
| Intraoperative RRT | |||
| No | 359 | 1.02 (0.99, 1.06) | 0.589 |
| Yes | 43 | 1.07 (0.98, 1.17) | |
| Post-transplant ammonia | |||
| ≤49 | 209 | 1.02 (0.98, 1.06) | 0.817 |
| >49 | 193 | 1.05 (1.00, 1.10) | |
| Post-transplant sedatives | |||
| No | 322 | 1.03 (1.00, 1.07) | 0.660 |
| Yes | 80 | 1.03 (0.96, 1.12) |
Note 1: Above model adjusted for age, gender, creatinine, international normalized ratio, sodium, malignancy, encephalopathy, artificial liver support, auto-transfusion, intraoperative renal replacement therapy, and post-transplant ammonia. Note 2: In each case, the model is not adjusted for the stratification variable. p < 0.05 was considered statistically significant. BMI, body mass index; MELD, model for end-stage liver disease; RBC, red blood cell; RRT, renal replacement therapy.